Latest news

Can investment in hepatitis C treatment be cost saving?

Visit our Liver Meeting 2020 conference pages.

Image: Gerd Altmann/Pixabay

Which people with chronic liver disease have higher COVID-19 risks?

Few countries will meet 2020 target for reducing viral hepatitis deaths

Keith Alcorn / 24 November 2020

Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of direct-acting antiviral treatment, according to analyses of ...
Antiviral therapy

Some hepatitis B patients can safely stop antivirals

Liz Highleyman / 24 November 2020

Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ...